Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…